MX372986B - Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) - Google Patents
Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)Info
- Publication number
- MX372986B MX372986B MX2017003627A MX2017003627A MX372986B MX 372986 B MX372986 B MX 372986B MX 2017003627 A MX2017003627 A MX 2017003627A MX 2017003627 A MX2017003627 A MX 2017003627A MX 372986 B MX372986 B MX 372986B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- idh
- inhibitors
- quinolinone
- pyrimidine
- Prior art date
Links
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 title abstract 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- GVPYUHDRBHTFOE-UHFFFAOYSA-N OC1=NC2=CC=CC=C2C=C1.N1=CN=CC=C1 Chemical compound OC1=NC2=CC=CC=C2C=C1.N1=CN=CC=C1 GVPYUHDRBHTFOE-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000003538 neomorphic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a inhibidores de proteínas de isocitrato deshidrogenasa mutante (mt-IDH) con actividad neomórfica útiles en el tratamiento de trastornos de proliferación celular y cánceres, que poseen la Fórmula: (ver fórmula), donde A, B, W1, W2, W3 y R1-R6 se describen la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053010P | 2014-09-19 | 2014-09-19 | |
| PCT/US2015/051044 WO2016044781A1 (en) | 2014-09-19 | 2015-09-18 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017003627A MX2017003627A (es) | 2018-01-24 |
| MX372986B true MX372986B (es) | 2020-03-31 |
Family
ID=55525126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003627A MX372986B (es) | 2014-09-19 | 2015-09-18 | Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9815817B2 (es) |
| EP (1) | EP3194383B1 (es) |
| JP (1) | JP6648116B2 (es) |
| AU (1) | AU2015317321B2 (es) |
| CA (1) | CA2961793C (es) |
| ES (1) | ES2768694T3 (es) |
| MX (1) | MX372986B (es) |
| WO (1) | WO2016044781A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10336768B2 (en) * | 2014-06-13 | 2019-07-02 | Yuma Therapeutics, Inc. | Pyrimidine compounds and methods using the same |
| LT3194376T (lt) | 2014-09-19 | 2019-02-25 | Forma Therapeutics, Inc. | Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitratdehidrogenazės inhibitoriai |
| US9771349B2 (en) | 2014-09-19 | 2017-09-26 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| AU2015317322B2 (en) | 2014-09-19 | 2020-09-17 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| MX372986B (es) | 2014-09-19 | 2020-03-31 | Forma Therapeutics Inc | Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US9624175B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| CN107216312B (zh) * | 2016-03-22 | 2023-08-01 | 上海海和药物研究开发股份有限公司 | 一种具有突变型idh抑制活性的化合物、其制备方法及用途 |
| CN110023298B (zh) * | 2016-11-24 | 2022-12-16 | 浙江迈同生物医药有限公司 | 异柠檬酸脱氢酶(idh)抑制剂 |
| WO2018118793A1 (en) * | 2016-12-19 | 2018-06-28 | Isocure Biosciences Inc. | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
| CN106831601A (zh) * | 2017-01-13 | 2017-06-13 | 河北博伦特药业有限公司 | 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法 |
| CN108558774A (zh) * | 2018-04-26 | 2018-09-21 | 南京药石科技股份有限公司 | 一种合成卤代-氨甲基取代嘧啶及其盐的方法 |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US20210196701A1 (en) | 2018-05-16 | 2021-07-01 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| CN110499091B (zh) * | 2019-08-16 | 2021-04-27 | 安徽省优亲科技发展有限公司 | 一种纳米银-壳聚糖改性聚苯磺酰胺抗菌涂层及其制法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| WO2004043936A1 (ja) * | 2002-11-14 | 2004-05-27 | Kyowa Hakko Kogyo Co., Ltd. | Plk阻害剤 |
| RU2284325C2 (ru) | 2003-12-17 | 2006-09-27 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе |
| WO2005095382A1 (ja) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
| WO2006054912A1 (fr) | 2004-11-18 | 2006-05-26 | Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' | Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base |
| TW200803855A (en) | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| WO2008010964A1 (en) | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| JP2010043004A (ja) | 2006-12-06 | 2010-02-25 | Dainippon Sumitomo Pharma Co Ltd | 新規2環性複素環化合物 |
| EP2509600B1 (en) | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2012006104A2 (en) | 2010-06-28 | 2012-01-12 | Academia Sinica, Taiwan | Compounds and methods for treating tuberculosis infection |
| CN102558049B (zh) | 2010-12-17 | 2015-02-04 | 中国科学院上海药物研究所 | 一类双香豆素类化合物及其制备方法和用途 |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| US20120184548A1 (en) | 2011-01-19 | 2012-07-19 | Romyr Dominique | Carboxylic acid aryl amides |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN103814020B (zh) | 2011-06-17 | 2017-07-14 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| EP2771337B1 (en) * | 2011-09-27 | 2017-08-02 | Novartis AG | 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh |
| JP6473330B2 (ja) | 2011-12-21 | 2019-02-20 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト | RalGTPアーゼを標的とする抗がん化合物及びその使用方法 |
| KR101893112B1 (ko) | 2012-01-06 | 2018-08-30 | 아지오스 파마슈티컬스 아이엔씨. | 치료학적으로 활성인 화합물 및 이의 이용 방법 |
| BR112015022483A2 (pt) | 2013-03-14 | 2017-07-18 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| PE20170143A1 (es) | 2014-02-11 | 2017-03-19 | Bayer Pharma AG | Benzimidazol-2-aminas como inhibidores de midh1 |
| LT3194376T (lt) * | 2014-09-19 | 2019-02-25 | Forma Therapeutics, Inc. | Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitratdehidrogenazės inhibitoriai |
| MX372986B (es) | 2014-09-19 | 2020-03-31 | Forma Therapeutics Inc | Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) |
| AU2015317322B2 (en) | 2014-09-19 | 2020-09-17 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9771349B2 (en) | 2014-09-19 | 2017-09-26 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| CN107428690B (zh) | 2014-12-22 | 2021-04-13 | 美国政府健康及人类服务部 | 可用于治疗癌症的突变idh1抑制剂 |
| GB2533925A (en) | 2014-12-31 | 2016-07-13 | Univ Bath | Antimicrobial compounds, compositions and methods |
| US9615817B2 (en) | 2015-02-27 | 2017-04-11 | Surgical Innovations Llc | Wound closure apparatus and method |
| US9624175B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US10253041B2 (en) | 2015-07-27 | 2019-04-09 | Eli Lilly And Company | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors |
| US10137130B2 (en) | 2016-02-26 | 2018-11-27 | Celgene Corporation | Methods of treatment of malignancies |
| CN109311863B (zh) | 2016-06-06 | 2021-10-29 | 伊莱利利公司 | 突变型idh1抑制剂 |
| CN109641887B (zh) | 2016-06-22 | 2022-09-20 | 美国政府健康及人类服务部 | 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 |
| EP3555105B1 (en) | 2016-12-16 | 2020-10-28 | Eli Lilly and Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
-
2015
- 2015-09-18 MX MX2017003627A patent/MX372986B/es active IP Right Grant
- 2015-09-18 EP EP15771463.5A patent/EP3194383B1/en active Active
- 2015-09-18 CA CA2961793A patent/CA2961793C/en not_active Expired - Fee Related
- 2015-09-18 JP JP2017515130A patent/JP6648116B2/ja not_active Expired - Fee Related
- 2015-09-18 WO PCT/US2015/051044 patent/WO2016044781A1/en not_active Ceased
- 2015-09-18 ES ES15771463T patent/ES2768694T3/es active Active
- 2015-09-18 US US14/858,165 patent/US9815817B2/en not_active Expired - Fee Related
- 2015-09-18 AU AU2015317321A patent/AU2015317321B2/en not_active Ceased
-
2017
- 2017-09-22 US US15/712,446 patent/US10280150B2/en not_active Expired - Fee Related
-
2018
- 2018-12-28 US US16/235,524 patent/US20190210995A1/en not_active Abandoned
-
2019
- 2019-03-01 US US16/290,328 patent/US10550099B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017003627A (es) | 2018-01-24 |
| US9815817B2 (en) | 2017-11-14 |
| WO2016044781A1 (en) | 2016-03-24 |
| JP2017528492A (ja) | 2017-09-28 |
| US20180134682A1 (en) | 2018-05-17 |
| US20190210995A1 (en) | 2019-07-11 |
| ES2768694T3 (es) | 2020-06-23 |
| US10550099B2 (en) | 2020-02-04 |
| CA2961793C (en) | 2021-03-16 |
| AU2015317321B2 (en) | 2020-03-12 |
| AU2015317321A1 (en) | 2017-05-04 |
| JP6648116B2 (ja) | 2020-02-14 |
| US20160083365A1 (en) | 2016-03-24 |
| CA2961793A1 (en) | 2016-03-24 |
| US10280150B2 (en) | 2019-05-07 |
| US20190263779A1 (en) | 2019-08-29 |
| EP3194383B1 (en) | 2019-11-06 |
| EP3194383A1 (en) | 2017-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX372986B (es) | Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) | |
| MX372964B (es) | Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) | |
| ZA202304409B (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| MX390347B (es) | Compuestos de aminotiazol como inhibidores de c-kit. | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| PH12018500177A1 (en) | Compositions useful for treating disorders related to kit and pdfgr | |
| EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
| MX2017006302A (es) | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| MX2017003626A (es) | Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). | |
| EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| UA117470C2 (uk) | Заміщені ксантини та способи їх застосування | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
| JO3722B1 (ar) | مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| ZA201904522B (en) | Heterocyclic inhibitors of mct4 | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| CL2016002839A1 (es) | Derivados de carboxamida | |
| EA201791530A1 (ru) | НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ | |
| EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |